MedTrace Logo

Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children

NCT02327936 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2019-07-30

No results posted yet for this study

Summary

The purpose of this study is to evaluate the tolerability of Fesoterodine and Oxytbutynin XL and to compare their efficacy for overactive bladder syndrome in children.

Conditions

Interventions

DRUG

Fesoterodine

Administer medication to patients with overactive bladder

DRUG

Oxybutynin XL

Administer medication to patients with overactive bladder

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Stéphane Bolduc

    lead OTHER

Principal Investigators

  • Stéphane Bolduc, MD · CHU de Québec-Université Laval

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
5 Years
Max Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2018-03-31
Completion
2018-08-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02327936 on ClinicalTrials.gov